vs
GoodRx Holdings, Inc.（GDRX）与LifeStance Health Group, Inc.（LFST）财务数据对比。点击上方公司名可切换其他公司
LifeStance Health Group, Inc.的季度营收约是GoodRx Holdings, Inc.的2.0倍（$382.2M vs $194.8M），LifeStance Health Group, Inc.净利率更高（3.1% vs 2.8%，领先0.3%），LifeStance Health Group, Inc.同比增速更快（17.4% vs -1.9%），LifeStance Health Group, Inc.自由现金流更多（$46.6M vs $31.6M），过去两年LifeStance Health Group, Inc.的营收复合增速更高（12.8% vs -0.8%）
GoodRx是一家美国医疗健康企业，运营着远程医疗平台以及可免费使用的网站与移动应用，服务覆盖美国超75000家药店，可为用户追踪处方药价格、提供药品优惠折扣券，还支持用户在线问诊，获取部分品类药物的处方。
LifeStance Health Group是美国的门诊行为健康服务提供商，支持线下面诊与远程诊疗两种服务模式，业务涵盖心理咨询、精神科诊疗、经颅磁刺激（TMS）以及氯胺酮治疗等。该公司曾多次因劳动违规、客户信息泄露及误导投资者相关问题遭遇诉讼。
GDRX vs LFST — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $194.8M | $382.2M |
| 净利润 | $5.4M | $11.7M |
| 毛利率 | — | — |
| 营业利润率 | 11.6% | 4.7% |
| 净利率 | 2.8% | 3.1% |
| 营收同比 | -1.9% | 17.4% |
| 净利润同比 | -19.5% | 264.1% |
| 每股收益（稀释后） | $0.02 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $194.8M | $382.2M | ||
| Q3 25 | $196.0M | $363.8M | ||
| Q2 25 | $203.1M | $345.3M | ||
| Q1 25 | $203.0M | $333.0M | ||
| Q4 24 | $198.6M | $325.5M | ||
| Q3 24 | $195.3M | $312.7M | ||
| Q2 24 | $200.6M | $312.3M | ||
| Q1 24 | $197.9M | $300.4M |
| Q4 25 | $5.4M | $11.7M | ||
| Q3 25 | $1.1M | $1.1M | ||
| Q2 25 | $12.8M | $-3.8M | ||
| Q1 25 | $11.1M | $709.0K | ||
| Q4 24 | $6.7M | $-7.1M | ||
| Q3 24 | $4.0M | $-6.0M | ||
| Q2 24 | $6.7M | $-23.3M | ||
| Q1 24 | $-1.0M | $-21.1M |
| Q4 25 | 11.6% | 4.7% | ||
| Q3 25 | 7.5% | 2.0% | ||
| Q2 25 | 13.2% | -0.9% | ||
| Q1 25 | 11.5% | 0.5% | ||
| Q4 24 | 9.2% | 0.3% | ||
| Q3 24 | 10.5% | 0.0% | ||
| Q2 24 | 9.9% | -5.1% | ||
| Q1 24 | 3.7% | -5.6% |
| Q4 25 | 2.8% | 3.1% | ||
| Q3 25 | 0.6% | 0.3% | ||
| Q2 25 | 6.3% | -1.1% | ||
| Q1 25 | 5.4% | 0.2% | ||
| Q4 24 | 3.4% | -2.2% | ||
| Q3 24 | 2.0% | -1.9% | ||
| Q2 24 | 3.3% | -7.5% | ||
| Q1 24 | -0.5% | -7.0% |
| Q4 25 | $0.02 | — | ||
| Q3 25 | $0.00 | — | ||
| Q2 25 | $0.04 | — | ||
| Q1 25 | $0.03 | — | ||
| Q4 24 | $0.01 | — | ||
| Q3 24 | $0.01 | — | ||
| Q2 24 | $0.02 | — | ||
| Q1 24 | $0.00 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $261.8M | $248.6M |
| 总债务越低越好 | $495.0M | $282.8M |
| 股东权益账面价值 | $616.3M | $1.5B |
| 总资产 | $1.4B | $2.2B |
| 负债/权益比越低杠杆越低 | 0.80× | 0.19× |
8季度趋势，按日历期对齐
| Q4 25 | $261.8M | $248.6M | ||
| Q3 25 | $273.5M | $203.9M | ||
| Q2 25 | $281.3M | $188.9M | ||
| Q1 25 | $301.0M | $134.3M | ||
| Q4 24 | $448.3M | $154.6M | ||
| Q3 24 | $423.8M | $102.6M | ||
| Q2 24 | $524.9M | $87.0M | ||
| Q1 24 | $533.3M | $49.5M |
| Q4 25 | $495.0M | $282.8M | ||
| Q3 25 | — | $284.6M | ||
| Q2 25 | — | $286.4M | ||
| Q1 25 | — | $288.2M | ||
| Q4 24 | $500.0M | $290.0M | ||
| Q3 24 | — | $287.3M | ||
| Q2 24 | — | $288.0M | ||
| Q1 24 | — | $288.8M |
| Q4 25 | $616.3M | $1.5B | ||
| Q3 25 | $600.7M | $1.5B | ||
| Q2 25 | $643.0M | $1.5B | ||
| Q1 25 | $654.3M | $1.5B | ||
| Q4 24 | $724.7M | $1.4B | ||
| Q3 24 | $696.4M | $1.4B | ||
| Q2 24 | $669.4M | $1.4B | ||
| Q1 24 | $631.1M | $1.4B |
| Q4 25 | $1.4B | $2.2B | ||
| Q3 25 | $1.3B | $2.1B | ||
| Q2 25 | $1.3B | $2.1B | ||
| Q1 25 | $1.3B | $2.1B | ||
| Q4 24 | $1.4B | $2.1B | ||
| Q3 24 | $1.4B | $2.1B | ||
| Q2 24 | $1.5B | $2.1B | ||
| Q1 24 | $1.5B | $2.1B |
| Q4 25 | 0.80× | 0.19× | ||
| Q3 25 | — | 0.19× | ||
| Q2 25 | — | 0.19× | ||
| Q1 25 | — | 0.20× | ||
| Q4 24 | 0.69× | 0.20× | ||
| Q3 24 | — | 0.20× | ||
| Q2 24 | — | 0.20× | ||
| Q1 24 | — | 0.20× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $57.6M |
| 自由现金流经营现金流 - 资本支出 | $31.6M | $46.6M |
| 自由现金流率自由现金流/营收 | 16.2% | 12.2% |
| 资本支出强度资本支出/营收 | 0.6% | 2.9% |
| 现金转化率经营现金流/净利润 | 6.06× | 4.93× |
| 过去12个月自由现金流最近4个季度 | $164.4M | $110.0M |
8季度趋势，按日历期对齐
| Q4 25 | $32.9M | $57.6M | ||
| Q3 25 | $76.0M | $27.3M | ||
| Q2 25 | $49.6M | $64.4M | ||
| Q1 25 | $9.4M | $-3.1M | ||
| Q4 24 | $44.7M | $62.3M | ||
| Q3 24 | $86.9M | $22.7M | ||
| Q2 24 | $9.7M | $44.1M | ||
| Q1 24 | $42.6M | $-21.8M |
| Q4 25 | $31.6M | $46.6M | ||
| Q3 25 | $74.3M | $17.0M | ||
| Q2 25 | $49.2M | $56.6M | ||
| Q1 25 | $9.3M | $-10.3M | ||
| Q4 24 | $44.6M | $56.0M | ||
| Q3 24 | $86.5M | $17.7M | ||
| Q2 24 | $9.4M | $39.0M | ||
| Q1 24 | $42.2M | $-26.9M |
| Q4 25 | 16.2% | 12.2% | ||
| Q3 25 | 37.9% | 4.7% | ||
| Q2 25 | 24.2% | 16.4% | ||
| Q1 25 | 4.6% | -3.1% | ||
| Q4 24 | 22.4% | 17.2% | ||
| Q3 24 | 44.3% | 5.7% | ||
| Q2 24 | 4.7% | 12.5% | ||
| Q1 24 | 21.3% | -9.0% |
| Q4 25 | 0.6% | 2.9% | ||
| Q3 25 | 0.9% | 2.8% | ||
| Q2 25 | 0.2% | 2.2% | ||
| Q1 25 | 0.1% | 2.2% | ||
| Q4 24 | 0.1% | 1.9% | ||
| Q3 24 | 0.2% | 1.6% | ||
| Q2 24 | 0.1% | 1.6% | ||
| Q1 24 | 0.2% | 1.7% |
| Q4 25 | 6.06× | 4.93× | ||
| Q3 25 | 67.94× | 25.34× | ||
| Q2 25 | 3.86× | — | ||
| Q1 25 | 0.85× | -4.36× | ||
| Q4 24 | 6.64× | — | ||
| Q3 24 | 21.91× | — | ||
| Q2 24 | 1.45× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GDRX
| Prescription Transactions Revenue | $124.7M | 64% |
| Other | $44.4M | 23% |
| Subscription Revenue | $21.6M | 11% |
| Other Revenue | $4.1M | 2% |
LFST
暂无分部数据
